2025-07-23 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc. (TGTX) based on the provided data, presented in English with simplified numerical summaries and analysis.

**Report: TG Therapeutics Inc. (TGTX) Analysis**

**1. Performance Overview**

*   **Ticker:** TGTX
*   **Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **Cumulative Return (TGTX):** 65.98%
*   **Cumulative Return (VOO - S&P 500):** 97.07%
*   **Performance Gap:** -31.09% (TGTX underperformed VOO by this amount over the period).
*   **Relative Performance Gap:** 15.6% (This means the current underperformance is relatively close to the best historical performance)

**Analysis of Alpha, Beta:**

| Year       | CAGR    | MDD   | Alpha    | Beta   | Cap(B) |
|------------|---------|-------|----------|--------|--------|
| 2015-2017  | -6.0%   | 56.5% | -35.0%   | -0.1   | 1.3    |
| 2016-2018  | -8.0%   | 58.6% | -26.0%   | 0.0    | 0.7    |
| 2017-2019  | 74.0%   | 58.6% | 44.0%    | 0.0    | 1.8    |
| 2018-2020  | 402.0%  | 58.6% | 382.0%   | -0.4   | 8.3    |
| 2019-2021  | 125.0%  | 63.5% | 76.0%    | -0.5   | 3.0    |
| 2020-2022  | -76.0%  | 70.4% | -78.0%   | -0.6   | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -368.0%  | -0.8   | 2.7    |
| 2022-2024  | 71.0%   | 73.1% | 45.0%    | -0.9   | 4.8    |
| 2023-2025  | 73.0%   | 73.1% | 24.0%    | 0.4    | 5.9    |

*   **CAGR Analysis:** The CAGR shows significant volatility over different periods, ranging from substantial losses to high growth.  The company has experienced high growth recently
*   **Alpha:**  Alpha is highly variable, indicating periods of significant outperformance and underperformance relative to the market. Recently, the Alpha has been high
*   **Beta:** The Beta values are generally low, suggesting the stock is less sensitive to market movements.
*   **MDD:** The high MDD figures indicate substantial risk and volatility.

**2. Recent Price Action**

*   **Current Price:** \$37.37
*   **Previous Close:** \$37.42
*   **Price Change:** -\$0.13
*   **5-Day Moving Average:** \$38.15
*   **20-Day Moving Average:** \$37.38
*   **60-Day Moving Average:** \$37.11

**Analysis:** The price is slightly below the 20-day moving average and close to the 60-day moving average, suggesting some short-term weakness but overall stability. The small price change indicates no significant short-term volatility.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 59.22 (Approaching overbought territory, but not there yet)
*   **PPO:** 0.0496 (Positive, indicating potential upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.33) (Cash Ratio: 0% on 2025-07-10)
*   **Recent (20-day) Relative Performance Gap Change:** -1.5 (Short-term decline)
*   **Expected Return (%):** -251.8% (Very negative, indicating significant underperformance is projected relative to the S&P 500 over the long term.)

**Analysis:** The MRI suggests a low-risk environment. The negative expected return is concerning. The short-term decline in relative performance aligns with the price being below the 5-day moving average.

**4. Recent News & Significant Events**

*   **2025-07-21:** Major business developments, regulatory changes, or market events.
*   **2025-07-20:** Analyst discussions of recent performance and outlook.
*   **2025-07-22:** Notable stock volatility.
*   **2025-07-23:** Market experts highlighting both risks and opportunities.

**Analysis:** The news suggests the company is experiencing significant events that are impacting its stock price. Volatility is a key factor to consider.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-09 | 0.03  | 0.12 B\$   |
| 2024-11-07 | 0.03  | 0.08 B\$   |
| 2024-08-09 | 0.05  | 0.07 B\$   |
| 2024-05-06 | -0.07 | 0.06 B\$   |
| 2025-05-09 | -0.07 | 0.06 B\$   |

**Analysis:** The company's recent earnings have shown a mixture of positive and negative EPS.  Revenue has generally been increasing.

**6. Financial Information:**

Revenue and Profitability:

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-03-31 | \$0.12B  | 87.14%        |
| 2024-12-31 | \$0.11B  | 85.77%        |
| 2024-09-30 | \$0.08B  | 88.86%        |
| 2024-06-30 | \$0.07B  | 88.70%        |
| 2024-03-31 | \$0.06B  | 91.43%        |

Capital and Profitability:

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-03-31 | \$0.24B  | 2.13%   |
| 2024-12-31 | \$0.22B  | 10.49%  |
| 2024-09-30 | \$0.19B  | 2.02%   |
| 2024-06-30 | \$0.18B  | 3.87%   |
| 2024-03-31 | \$0.16B  | -6.69%  |

**Analysis:** Revenue has been growing consistently. Profit margins are exceptionally high. ROE has been volatile, suggesting inconsistent profitability relative to equity.

**7. Overall Analysis**

TG Therapeutics Inc. (TGTX) presents a mixed picture.

*   **Positives:** Recent revenue growth, high profit margins, and a low MRI indicating lower market risk.  RSI is approaching overbought condition
*   **Negatives:**  Significant underperformance compared to the S&P 500, historical volatility, recent negative expected return (suggesting projected underperformance), and mixed earnings results.

**Conclusion:**

TGTX appears to be a high-risk, high-reward stock. While recent financial performance is positive, historical volatility and negative long-term expected returns should give investors pause. The company is undergoing significant events, requiring close monitoring. The high-profit margin suggests it has a strong business model. Further investigation into the regulatory changes, market events, and analyst outlook is warranted before making any investment decisions.
